Article: Curis Announces Phase II Clinical Plan for Hedgehog Antagonist Presented by Collaborator Genentech.

Genentech indicates that it expects to initiate three Phase II clinical trials of GDC-0449 in 2008

CAMBRIDGE, Mass. -- Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing novel targeted medicines primarily for cancer treatment, today announced that its collaborator Genentech provided an update on its Phase II clinical trial plans for GDC-0449. GDC-0449 is an orally-administered small molecule antagonist of Hedgehog signaling and is being developed pursuant to the parties' June 2003 collaboration agreement. Genentech also announced that it has seen partial responses in advanced basal cell carcinoma tumors in the ongoing Phase I clinical trial of ...

Related newspaper, magazine, and journal articles:

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!